Opus Point Partners Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Opus Point Partners Management’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-69,109	Closed	-$763K	–	44
2016 Q1	$763K	Buy	69,109 +12,321	+22%	+$122K	0.59%	38
2015 Q4	$693K	Hold	56,788	–	–	0.46%	50
2015 Q3	$926K	Buy	56,788 +5,000	+10%	+$110K	0.51%	30
2015 Q2	$1.1M	Buy	51,788 +10,000	+24%	+$179K	0.87%	32
2015 Q1	$751K	Hold	41,788	–	–	0.63%	42
2014 Q4	$716K	Buy	+41,788	New	+$597K	0.71%	41

Other funds holding AVDL

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

FPC

Falcon Point Capital San Francisco, California $11.9M AUM 55.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

Opus Point Partners Management's AVDL Position: Q2 2016 in Review

Opus Point Partners Management sold out of Avadel Pharmaceuticals (AVDL) in Q2 2016, closing a stake of 69,109 shares — an estimated $763K sold.

Opus Point Partners Management first reported a position in AVDL in Q4 2014 and held it in 6 quarters. The position peaked at $1.1M in Q2 2015. 84 funds tracked by Wall St. Rank hold AVDL as of Q2 2016.

Opus Point Partners Management reported no remaining Avadel Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
Opus Point Partners Management sold 69,109 Avadel Pharmaceuticals shares in Q2 2016, an estimated $763K.
Opus Point Partners Management first reported a position in Avadel Pharmaceuticals in Q4 2014 and held it in 6 quarters.
Opus Point Partners Management's Avadel Pharmaceuticals position peaked at $1.1M in Q2 2015.
84 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q2 2016.

Based on Opus Point Partners Management's 13F filing for Q2 2016, filed 15 Aug 2016.